Background: Skin denervation that develops in patients with diabetes mellitus as a neuropathic manifestation is known as diabetic peripheral neuropathy (DPN). Skin denervation is parallel to neuronal injuries that alter intracellular signaling. To date, the correlation between nerve injury and the activation of intracellular responses to neuropathic manifestations has not been elucidated; specifically, whether activating transcription factor 3 (ATF3) is responsible for neuronal injury and a critical molecule that modulates the activation of intracellular protein kinase C epsilon (p-PKCε) and pain development in DPN is a crucial question. 
Introduction
Patients with chronic diabetes mellitus often develop diabetic peripheral neuropathy (DPN), which is an epidemiological problem and a clinical challenge that has no satisfactory therapy. [1] [2] [3] [4] In pathophysiological terms, DPN is the result of damage to peripheral nerves that alters intracellular responses at the neuronal soma level. [5] [6] [7] [8] Specifically, these nerve injuries result in skin denervation and cause a cascade of responses in neuronal cell bodies; that is, transcription factors are upregulated, leading to the generation of effector molecules that are responsible for maladaptive behaviors in neuropathic pain.
Activating transcription factor 3 (ATF3) is a member of the ATF/CREB transcription factor superfamily 9 and is upregulated in dorsal root ganglia (DRG) neurons after nerve injury; for example, spinal nerve ligation 10 and small fiber neuropathy with skin denervation markedly increased ATF3 expression in purinergic P2X3 nociceptors 11 as well as in antinociceptive-mediating neurons, 12 both of which are correlated with neuropathic pain. Accordingly, ATF3 upregulation is not only an indicator of injury but also correlated with the increasing ligand concentration of purinociceptor, 11 altering the neurophysiological responses of primary afferent nociceptors. Nevertheless, intracellular responses caused by injured neurons in DPN remain unclear; therefore, they are worthy of investigation. Specifically, ATF3 upregulation coincided with the maladaptive behavior of small fiber neuropathy, 11, 12 suggesting ATF3 to be an upstream molecule that modulates the changes of intracellular signaling. Protein kinase C epsilon (PKCε) is an intracellular second messenger in primary afferent nociceptors that modulates neuropathic pain, 13 and PKCε inhibition alleviated symptoms in several skin denervationassociated neuropathic pain models. [14] [15] [16] [17] [18] Collectively, these observations raise the following crucial question that requires elucidating: does ATF3 modulate the expression of PKCε, thereby mediating neuropathic manifestations? 19 Nerve injury is a major cause of pathology, which leads to painful diabetic neuropathy. B-cell lymphoma-extra large (Bcl-XL ), a protein of the antiapoptotic Bcl2 family, plays a role in regulating the cellular energy homeostasis that underlies cellular stress. 20 Therefore, Bcl-XL might act as a signaling molecule that responds to nerve injury; in particular, Bcl-XL has received limited attention in terms of pain development, 21 which is modulated by ATF3 underneath the nerve injury condition. Collectively, ATF3 upregulation may be correlated with the coexpression of PKCε and Bcl-XL , which mediates pain development. To address the aforementioned problems, this study used ATF3 knockout (atf3 −/− ) mice and compared them with wild-type mice to investigate whether ATF3 knockout prevents the development of neuropathic manifestations through the downregulation of PKCε(+): Bcl-XL (+) neurons, although underlying the nerve injury condition.
Materials and methods

DPn induction and animal grouping
A mouse model of DPN was established using 8-week-old adult C57/B6 mice as well as age-matched atf3 −/− mice 22 with a C57/B6 genetic background (a gift from Dr Tsonwin Hai, Ohio State University, Columbus, OH, USA). Briefly, streptozotocin (STZ; Sigma, St. Louis, MO, USA) was dissolved in citrate buffer (pH =5.5; Sigma), and mice were administered a single dose of STZ (200 mg/kg) through intraperitoneal injection. The blood glucose level was examined weekly by using a commercially available glucometer (Accu-Chek Go, Roche Diagnostics GmbH, Mannheim, Germany). Accordingly, our preliminary test showed that hyperglycemia was induced after 1 week of STZ administration with an approximately 92% survival rate (33/36 mice) with this STZ dose. Mice that showed severe hyperglycemia (glucose level >400 mg/dL) at day 7 after STZ administration were included and those that showed mild to moderate hyperglycemia (glucose level <400 mg/dL) were assigned to the non-DPN (nDPN) group. This study had four groups: (1) atf3 +/+ (wild-type mice); (2) atf3 −/− (atf3 −/− mice); (3) nDPN (served as the positive control); and (4) citrate group (a group of mice that received an equal volume of citrate solution, which served as the negative control). Mice were housed in plastic cages in a 12-hour light/12-hour dark cycle with access to water and food ad libitum. All experiments in this report included the behavioral tests and double-labeling immunostaining and were performed in each group during posttreatment month 2 (PTM2) when neuropathic manifestations reached an apex according to our preliminary observations. All procedures were performed in a coded and blinded manner and conducted in accordance with the published ethical guidelines for investigations of experimental pain in conscious animals. 23 All efforts were undertaken to reduce animal suffering, and the protocols were approved by the Institutional Animal Care and Use Committee of Kaohsiung Medical University.
Genotyping was performed using PCR by using genomic DNA extracted from the tail. Total DNA was extracted from tail tissues by using a Wizard Genomic DNA Purification Kit (Promega Corporation, Madison, WI, USA). Three primers were used in PCR: 5′-AGAGCTTCAGCAATGGTTTGC-3′ (primer 1), 5′-TGAAGAAGGTAAACACACCGTG3′ (primer 2), and 5′-ATCAGCAGCCTCTGTTCCAC-3′ (primer 3). Single-strand cDNA was amplified by 30 cycles of PCR. The PCR protocol used was as follows: 4 minutes of heating followed by 30 seconds of denaturation at 95°C; 30 seconds of annealing at 60°C; and 30 seconds of extension at 72°C. PCR products were electrolyzed using 1.5% agarose gel, and the PCR product was of 236 bp for the atf3 −/− group and 329 bp for the wild-type mice.
Behavioral evaluation
The behavioral evaluation included thermal and mechanical responses, which were tested using the hot plate test and von Frey hair test, respectively. 
von Frey hair test
The changes in the mechanical threshold of animal were evaluated using the up-and-down method by different calibers of von Frey hairs (Somedic Sales AB, Hörby, Sweden) in accordance with our established protocol. 11, 24 Briefly, a series of hairs was applied to the plantar of the hind paw. If paw withdrawal occurred, a hair with a smaller caliber was applied. In case of the absence of paw withdrawal, a hair with a larger caliber was applied. Four additional applications of hairs with various calibers were applied according to previous preceding responses, and mechanical thresholds of each animal were calculated using a previously published formula. 25 evaluation and quantitation of protein gene product (PgP) 9.5(+) intraepidermal nerve fibers (IENFs) immunohistochemistry of PgP 9.5(+) ienFs Skin innervation was evaluated using a pan-axonal marker, PGP 9.5, with the immunohistochemical studies. For evaluation of PGP 9.5(+) IENFs, the intracardiac perfusion was performed on animal with 0.1 M phosphate buffer (PB), followed by 4% paraformaldehyde (4P) in 0.1 M PB. After perfusion, footpad skin was postfixed for another 6 hours and stored in PB. For cryosection, footpad skin was cryoprotected with 30% sucrose in PB overnight and sectioned perpendicular to the epidermis in a 30 µm thickness on an HM440E sliding microtome (Microm, Walldorf, Germany). For adequate sampling, every third section of each footpad and six sections were chosen, and briefly, the sections were quenched with 1% H 2 O 2 in methanol and blocked with 0.5% nonfat dry milk and 0.1% TritonX-100 in 0.5M Tris buffer (Tris). Footpad sections were incubated with anti-PGP 9.5 (1:1,000, UltraClone, Isle of Wight, UK) antiserum overnight at 4°C. After rinsing with Tris, the footpad sections were then incubated with biotinylated secondary antiserum (Vector, Burlingame, CA, USA) and with avidin-biotin complex (Vector). The reaction product was demonstrated using 3,3′-diaminobenzidine (Sigma), and the sections were mounted on gelatin-subbed slides for further analyses.
Quantitation of PgP 9.5(+) ienFs PGP 9.5(+) IENFs were counted under 400× magnification (Axiophot microscope, Carl Zeiss, Oberkochen, Germany) and following established criteria in a coded fashion. 26, 27 IENFs with branching points within the epidermis were calculated as a single IENF, and those IENF with branching points in the dermis were counted as single IENF. The length in the lower border of the stratum corneum was defined as the epidermal length and was determined with ImageJ version 1.44d (National Institutes of Health, Bethesda, MD, USA). The IENF density was defined as the number of IENF divided by the epidermal length (fibers/mm).
Double-labeling immunofluorescence staining of DRg neurons
The fourth and fifth lumbar (L4 and L5, respectively) DRGs were postfixed for another 6 hours. The DRG tissues were cryoprotected with same protocol of footpad skin, and cryosections were cut in 8 µm thickness using a cryostat (CM1850; Leica, Wetzlar, Germany). To ensure adequate sampling, five to eight sections per DRG tissue and both L4 and L5 DRG tissues per mouse were immunostained. Primary antisera included anti-ATF3 (rabbit, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), antiphosphorylated PKCε (p-PKCε, goat, 1:200; Santa Cruz Biotechnology), and anti-Bcl-XL (rabbit, 1:250; Cell Signaling, Danvers, MA, USA). There were two combinations of primary antisera: (1) ATF3:p-PKCε and (2) Bcl-XL :p-PKCε. Briefly, sections were incubated with primary antisera combinations overnight, followed with Texas Red and fluorescein isothiocyanate (FITC)-conjugated secondary antisera (1:100; Jackson ImmunoResearch, West Grove, PA, USA) corresponding to appropriate primary antisera for 1 hour.
Quantification of different phenotypic DRg neurons
To quantify the different phenotypic DRG neurons, each DRG section was systematically photographed at 200× under a fluorescence microscope (Carl Zeiss) with appropriate filters. A montage of the entire DRG section was obtained according to our established protocols. 11, 24, 27 Ganglia neurons were gathered together and were larger than other cell types, such as fibroblasts, in a DRG section. To identify labeled neurons, optical intensities between immunoreactive and background neurons were determined. On a 0-255 scale, a preliminary analysis showed the optical intensities of FITC to be in the range of 130-255, and similarly, the optical intensities of Texas Red were shown to be in the range of 121-252. Each signal of a fluorochrome below these ranges acted as the background. To avoid bias, only neurons with a clear nuclear profile and an intensity threshold that met the criteria were counted, and only areas containing ganglia neurons were measured using ImageJ version 1.44d. In addition, the ratios of p-PKCε(+) and Bcl-XL (+) neurons in whole DRG neurons were calculated by dividing the total numbers of DRG neurons, which were obtained using a Nomarski differential interference contrast filter ( Figure S1 ).
statistical analyses
To reduce individual variations, each group composed five to eight animals, and coding information was masked during behavioral tests and all quantification procedures. All data are expressed as the mean ± SD of the mean, and a t-test was performed for data with a Gaussian distribution. Data without a Gaussian distribution were analyzed using the nonparametric Mann-Whitney U test. In behavioral studies and physiological examinations, one-way repeated-measures ANOVA was performed, followed by Tukey's post hoc test when a significance level of P<0.05 was obtained.
Results
aTF3 knockout prevented neuropathic manifestation of sTZ-induced DPn
Compared with the citrate and nDPN groups, STZ induced hyperglycemia in the atf3 +/+ group at 1 week after STZ administration until PTM2 ( Figure 1A) . Hyperglycemia was not reversed in the aft3 −/− group, and body weight changes in the aft3 −/− group were comparable with those in the atf3 +/+ group ( Figure 1B) . The development of thermal hyperalgesia ( Figure  1C ) and mechanical allodynia ( Figure 1D) Figure 1C, D) .
skin denervation after sTZ-induced DPn
Skin denervation was associated with thermal hyperalgesia (Figure 2 ). PGP9.5(+) IENFs arose from the subepidermal plexus with a varicose appearance in the citrate and nDPN group (Figure 2A, D) , and these PGP9.5(+) IENFs were markedly decreased in the atf3 +/+ (10.8±3.9 vs 2.6±2.0 fibers/mm; P<0.001) and aft3 −/− groups (2.9±1.7 fibers/mm; P<0.001) ( Figure 2B, C, E) . Paradoxically, the results of linear analyses showed that the densities of PGP9.5(+) IENFs were correlated with their thermal latencies (r=0.64, P=0.006; Figure 2F ), but no relationship was revealed with the mechanical thresholds (r=0.46, P=0.07; Figure 2G ).
Upregulation of p-PKcε:aTF3 in smalldiameter neurons after sTZ-induced DPn
We examined the profiles of p-PKCε(+):ATF3(+) neurons by performing double-labeling immunostaining to investigate (wild-type mice with blood glucose >400 mg/dL, filled bar), atf3 −/− (aTF3 knockout mice with blood glucose >400 mg/dl, dotted bar), and nDPn (blood glucose <400 mg/dl, slashed bar) groups, respectively, as described in the Materials and methods section. (A, B) The graphs show the changes in blood glucose (A) and body weight (B) for each group. (C, D) The graphs show the changes in thermal latency (B) and mechanical threshold (C) of each group. aTF3 knockout relieved the degree of neuropathic manifestation. *P<0.05, **P<0.01, ***P<0.001: atf3
−/− groups compared with the citrate group.
• P<0.05, 
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aTF3 modulates diabetic peripheral neuropathy whether p-PKCε was activated by injured neurons that were parallel to skin denervation ( Figure 3 ). In the citrate group, PKCε(+) neurons belonged to small-diameter neurons and no ATF3 upregulation occurred ( Figure 3A , E, I). Notably, ATF3 was upregulated (27.0±10.7 vs 2.9±2.9 neurons/mm 2 ) in the atf3 +/+ group ( Figure 3B , F, J, M). Moreover, these ATF3(+) neurons were colocalized with p-PKCε(+) neurons at ratios of 37.7% ± 6.1% vs 0.2% ± 0.4% ( Figure 3N ). Predictably, no ATF3 expression occurred in the atf3 −/− group ( Figure  3C , G, K), and only limited ATF3 upregulation occurred in the nDPN group ( Figure 3D, H, L) . Furthermore, the results of linear analyses showed the ratios of p-PKCε(+):ATF3(+) neurons to be antiparallel to the thermal latencies ( Figure  3O ) and mechanical thresholds ( Figure 3P ).
co-upregulation of p-PKcε(+) and Bcl-Xl (+) neurons was correlated with neuropathic manifestation after sTZinduced DPn
The results of double-labeling studies indicated that Bcl-XL (+) ( Figure 4M ). In addition, no density changes occurred in the total DRG neurons among each group, and the colocalized ratios of p-PKCε:Bcl-XL neurons increased by approximately two-fold in the atf3 +/+ group compared with the atf3 −/− group (30.0% ± 3.4% vs 13.7% ± 6.2%, P=0.003) ( Figure S1 ).
The densities of p-PKCε(+) ( Figure 4N ) and Bcl-XL (+) neurons ( Figure 4O ) had a reverse linear relationship with thermal latencies. Similar relationships existed with mechanical thresholds (Figure 4P, Q) . Collectively, the molecular significance of the upregulation of p-PKCε and Bcl-XL reflected the degree of neuropathic manifestations after STZ-induced DPN.
Discussion
This study discovered a new molecular mechanism underlying pain development: ATF3 is an upstream modulator that regulates the expression of p-PKCε: Bcl-XL , which 
sTZ-induced DPn shared pathological characteristics with small fiber neuropathy
A decreased density of IENFs on the hind paw skin is known as skin denervation, which is a remarkable pathological characteristic of small fiber neuropathy. Traditionally, PGP9.5 is widely used as a pan-axonal marker to label IENFs, and the evaluation of PGP9.5(+) IENFs densities using skin biopsy is a reliable clinical procedure for evaluating maladaptive neuropathic behaviors. 28, 29 For example, the densities of PGP9.5(+) IENFs were correlated with the degree of thermal hyperalgesia after DPN. Paradoxically, PGP9.5(+) IENFs were not linear to the thresholds of mechanical allodynia after DPN in this study. These findings imply that the injured neuronal soma required intracellular molecules, which could reflect neuropathic manifestations. ATF3 is a candidate molecule; it was traditionally considered a stress sensor and also correlated to neuropathic behavior by ATF3 expressed by the different phenotypic small-diameter neurons. 11, 12 This study further strengthens this speculation according to hyperglycemia and PGP9.5(+) IENF reductions, which were significant in both the atf3 +/+ and atf3 −/− groups; however, only the atf3
group exhibited maladaptive neuropathic behaviors. ATF3 acted on glucose homeostasis 30 and tolerance 31 in opposite effects, and accordingly, ATF3 is suggested an epiregulator 
, atf3
• that follows the downstream of intracellular signaling alternations. In this study, the mouse model of DPN mimicked patients with DPN who exhibit major characteristics of small fiber neuropathy, such as pathological skin denervation and altered intracellular molecular responses, and ATF3 was determined to be a potential molecule that mediates maladaptive neuropathic behavior.
C i t r a t e a t f 3 + / + a t f 3 -/ -n D P N C i t r a t e a t f 3 + / + a t f 3 -/ -
aTF3 is an upstream modulator of maladaptive neuropathic behavior after DPn DPN mice exhibited an antiparallel fashion of IENF reduction and ATF3 upregulation; that is, DPN extensively affected the neuronal soma and their peripheral terminals. ATF3 upregulation has been associated with increased ATP, which sensitized the P2X3 purinociceptor, 11 and reduced adenosine, which mediated the antinociceptive effect. 12, 32 The susceptible small-diameter neurons have created further challenges in distinguishing the contributions made by changing intracellular signaling molecules. Although ATF3 upregulation was injury-inducible 33 and cell type specific, 33, 34 the responses of the neuronal soma in patients with DPN, which contributed to neuropathic pain through modulated intracellular signaling molecules, remain ambiguous. The co-upregulation of ATF3 and p-PKCε determined the degrees of neuropathic behavior, and the linear analyses strengthened the molecular significance of p-PKCε. Intriguingly, the ratio of p-PKCε(+):ATF3(+) neurons was limited, implying the existence of a signaling enhancement that is modulated by p-PKCε-dependent signaling cascades. For example, Bcl-XL , a neuroprotective molecule, 20 may be a downstream candidate molecule.
This report suggested that the co-upregulation of p-PKCε(+) and Bcl-XL (+) neurons was neuronal injury dependent, which was reversed in the atf3 −/− group. Collectively, this report suggests that ATF3, a stress-inducible gene, modulated the profile expression of p-PKCε and Bcl-XL , which was correlated with the development of neuropathic behavior. Paradoxically, recent reports have indicated that ATF2 -but not ATF3 -is responsible for neuropathic pain. 35 Our previous studies reported ATF3 preferentially on small-diameter DRG neurons, 11, 12 and in those cases, we suggested that the role of ATF3 is more convincing in small-diameter neuropathy. However, the colocalization of p-PKCε(+):ATF3(+) neurons and p-PKCε(+):Bcl-XL (+) neurons provided limited evidence of molecular interactions. Therefore, these topics require further investigation.
Modulation of the expression of p-PKCε(+):Bcl-XL(+) signaling molecules is a new direction for pain control in diabetes mellitus-induced DPN.
DPN-associated maladaptive neuropathic behavior remains a clinical challenge, and current therapeutic interventions are merely satisfactory in clinics. This study indicated that the densities of p-PKCε(+) and Bcl-XL (+) neurons were linear to the degree of neuropathic behavior, which explains that p-PKCε and/or Bcl-XL are potential targets for relieving pain associated with ATF3 upregulation; this molecule could not be genetically depleted under normal conditions. For example, PKCε inhibition alleviated symptoms in several skin denervation-associated neuropathic pain models. [14] [15] [16] [17] [18] 36, 37 The antiapoptotic effect of Bcl-XL has been addressed in relevant studies, but this is the first report to indicate that the neuropathological profile of Bcl-XL is correlated with maladaptive neuropathic behavior. A report demonstrated that ATF3 possessed transcriptional repression of Bcl-XL activity, 38 which suggested that Bcl-XL activity is correlated with ATF3, although this report still lacks direct evidence linking these two molecules. In addition, the linkage of injury to the activation of p-PKC and Bcl-XL remains unclear; for example, whether Bcl-XL is the downstream effector of PKCε-dependent signaling cascades as well as the cascade sequence between p-PKCε and Bcl-XL require further investigation.
Collectively, the current report revealed that ATF3 is an intracellular upstream molecule that modulates the development of neuropathic manifestations in DPN.
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